Pfiz­er, Mer­ck KGaA hit the brakes on an­oth­er PhI­II as PD-L1 Baven­cio flops yet again

Pfiz­er and Mer­ck KGaA are ce­ment­ing in their dis­tant run­ner-up sta­tus for Baven­cio (avelum­ab), a PD-L1 check­point that just failed its fourth late-stage tri­al. And the drum­beat of set­backs — at a time check­points are pro­lif­er­at­ing around the world — will hurt their prospects for mak­ing this the block­buster they both need.

This time around re­searchers sim­ply said that Baven­cio in com­bi­na­tion with or fol­low­ing chemo in front­line ovar­i­an can­cer cas­es had failed the pri­ma­ry end­point on pro­gres­sion-free sur­vival, forc­ing them to draw a halt to the work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.